[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592419":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":16,"armGroups":24,"interventions":36,"overallOfficials":16,"centralContacts":54,"locations":64,"responsibleParty":80,"collaborators":16,"id":82,"slug":16,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":16,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":90,"maxAge":16,"enrollmentInfo":91,"targetDuration":16,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":16,"overallStatus":100,"whyStopped":16,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"AUCt","area under the curve","pre-dose~72 hours post-dose",{"measure":14,"description":15,"timeFrame":12},"Cmax","maximum plasma concentration",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":20,"primaryPurpose":21,"observationalModel":16,"timePerspective":16,"maskingInfo":22},"RANDOMIZED","CROSSOVER","DA-5222, DA-5222-R1, DA-5222-R2, DA-5222-R3","TREATMENT",{"masking":23,"maskingDescription":16,"whoMasked":16},"NONE",[25,33],{"label":26,"type":27,"description":16,"interventionNames":28},"Sequence A","EXPERIMENTAL",[29,30,31,32],"Drug: DA-5222","Drug: DA-5222-R1","Drug: DA-5222-R2","Drug: DA-5222-R3",{"label":34,"type":27,"description":16,"interventionNames":35},"Sequence B",[29,30,31,32],[37,42,46,50],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":16},"DRUG","DA-5222","single dose administration (DA-5222 one tablet once a day)",[26,34],{"type":38,"name":43,"description":44,"armGroupLabels":45,"otherNames":16},"DA-5222-R1","single dose administration (DA-5222-R1 one tablet once a day)",[26,34],{"type":38,"name":47,"description":48,"armGroupLabels":49,"otherNames":16},"DA-5222-R2","single dose administration (DA-5222-R2 one tablet once a day)",[26,34],{"type":38,"name":51,"description":52,"armGroupLabels":53,"otherNames":16},"DA-5222-R3","single dose administration (DA-5222-R3 one tablet once a day)",[26,34],[55,60],{"name":56,"role":57,"phone":58,"phoneExt":16,"email":59},"Jihyun Sung","CONTACT","+82-02-920-8369","jhsung@donga.co.kr",{"name":61,"role":57,"phone":62,"phoneExt":16,"email":63},"Heechan Jung","+82-02-920-8322","hcjung@donga.co.kr",[65],{"facility":66,"status":16,"city":67,"state":68,"zip":69,"country":68,"countryCode":16,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Bumin Hospital","Seoul","South Korea","07590",{"type":71,"coordinates":72},"Point",[73,74],126.9784,37.566,{"lat":74,"lon":73},[77],{"name":78,"role":57,"phone":16,"phoneExt":16,"email":79},"Taegon Hong, Ph.D","tghong@bumin.co.kr",{"type":81,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100592419",false,"NCT06993181","Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy volunteers\n* BMI between 18 and 30 kg\u002Fm2\n* Body weight: Male≥50kg, Female≥45kg\n* Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study\n\nExclusion Criteria:\n\n* Subjects with clinically significant medical history\n* Subjects with history of drug abuse or addicted\n* Subjects with allergy or drug hypersensitivity",true,"ALL","19 Years",{"count":92,"type":93},48,"ESTIMATED","INTERVENTIONAL",[96],"PHASE1","This study is to compare pharmacokinetics and safety profiles of DA-5222 single-administration and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects",[99],"Healthy","NOT_YET_RECRUITING","2025-06-03",{"date":103,"type":104},"2025-06-06","ACTUAL",{"date":106,"type":93},"2025-06",{"date":108,"type":93},"2025-07",{"name":5,"class":6},1]